GlassScriptPhysician profile
Mariem Abdou
NPI 1366882458
$853.70
in general payments reported to CMS, 2019-2025
8 companies · $150 in 2025
The $150 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $435 · 2020: $20.33 · 2021: $88.00 · 2022: $79.42 · 2023: $80.62 · 2025: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $230.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $215.04 | 2019 | |
| Allergan, INC. | $179.41 | 2019-2021 | |
| Abbvie INC. | $160.04 | 2022-2023 | |
| Tarsus Pharmaceuticals, INC. | $150.00 | 2025 | |
| Topcon Healthcare, INC. | $85.48 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $22.32 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $21.08 | 2019 | |
| Aerie Pharmaceuticals, INC. | $20.33 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mariem Abdou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.